Preface . 4 Scientific Program . 6 Posters . 12 List of Speakers . 18 Information . 24 11 credit hours (CME) have been awarded to the Symposium 207 by the European Union of Medical Specialists (UEMS) - European Board of Gastroenterology . 3 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 3 30.03.17 10:49 Preface In recent years medicine has witnessed an astonishing paradigm shift . For decades it was believed that for most diseases the individual risk was defined by the genetic make-up, potentially modified by the environment and lifestyle-factors . It has now emerged that the gut microbiome plays an equally important role for many gastrointestinal and non-gastrointestinal disorders . This opens astonishing new avenues to understand and target disease mechanisms in particular in relation to immune mediated diseases but might be equally important for the prevention of disease . Thus the organisers Gerald Holtmann and Mark Morrison from Brisbane, Nicholas Talley from Newcastle, William Chey from Ann Arbor, and Peter Gibson from Melbourne in close collaboration with other experts in the field have developed a scientific program that brings together basic scientists and clinicians from many disciplines to define our current knowledge and define future directions that are relevant for the translation of this knowledge into clinical practice . On behalf of the scientific committee Prof . Gerald Holtmann, Brisbane 4 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 4 30.03.17 10:49 Symposium 207 Gut Microbiome and Mucosal or Systemic Dysfunction: Mechanisms, Clinical Manifestations and Interventions May 19 – 20, 2017 Brisbane Convention & Exhibition Centre Scientifi c Organization: Prof . Gerald Holtmann Brisbane, Australia Princess Alexandra Hospital University of Queensland 199 Ipswich Road Brisbane, QLD 4102, Australia Telephone: +617 31 76 77 92 Telefax: +617 31 76 51 11 Registration: E-Mail: g .holtmann@uq .edu .au Thursday, May 18, 2017 16 .00 – 21 .00 h Scientifi c Co-Organization: at the congress offi ce W .D . Chey, Ann Arbor (USA) P .R . Gibson, Melbourne (Australia) Congress Venue: M . Morrison, Brisbane (Australia) Brisbane Convention & M . Simrén, Gothenburg (Sweden) Exhibition Centre N .J . Talley, Newcastle (Australia) Merivale St & Glenelg Street Offi cial Language: South Brisbane, QLD 4101 English Australia Posters: The Symposium 207 is organized A poster session will take place . by Falk Foundation e.V. For details see page 12 . 5 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 5 30.03.17 10:49 Friday, May 19, 2017 8.30 Welcome G . Holtmann, Brisbane 8.40 Associate Director General, Department of Science, C . Williams, Information Technology and Innovation Brisbane Session I The fundamentals and how to determine what really matters Chair: H .M . Mitchell, Sydney; G . Tyson, Brisbane 8.50 State-of-the-Art Lecture: Prevalent but uncharacterised microbial populations in P . Hugenholtz, the human gut microbiome Brisbane 9.25 Crosstalk between microbiota, pathogens and the J . Wehkamp, innate immune responses Tübingen 9.45 Morphology of inflammatory changes of the mucosa: M .M . Walker, Time to reassess inflammatory responses of the mucosa Newcastle 10.05 Making it all fit – Statistical challenges and new data K -A. Le Cao, analysis methods for integrating microbiome data with Brisbane other clinical measures 10.25 Assessment of symptoms in FGID and IBD studies M .P . Jones, that target the GI microbiome Sydney 10.45 Coffee break with poster session Session II Microbiome-host interactions Chair: M . Morrison, Brisbane; C . O’Brien, Canberra 11.15 State-of-the-Art Lecture: Faecalibacterium prausnitzii and other next-generation P . Langella, probiotics to prevent and to treat gastrointestinal Jouy-en-Josas disorders and diseases in humans 11.45 Does host genotype shape the gut microbiome? M -E. Costello, Brisbane 12.05 How does the gut microbiota affect the epigenome? M V. Joglekar, Sydney 6 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 6 30.03.17 10:49 Friday, May 19, 2017 12.25 A question of culture? Development and differentiation P . O Cuiv, of the mucosal and luminal microbiomes Brisbane 12.45 The role of mucins in shaping the microbiome? M . McGuckin, Brisbane 13.05 How does epithelial cell stress affect the nutrient and S . Keely, physical landscapes of the microbiome? Newcastle 13.25 Oral poster presentation: The induction of dysbiosis in the small intestine G . Burns, promotes allergic sensitisation Newcastle 13.35 Oral poster presentation: Faecal supernatants from patients with diarrhoea H . Wardill, predominant IBS disrupt colonic epithelial barrier Adelaide function and directly affect colorectal afferent nerves 13.45 Lunch with poster session Session III The gastrointestinal microbiome, diet and management of chronic diseases Chair: E . Powell, Brisbane; S . Roberts, Melbourne 14.45 Microbes affecting gastrointestinal growth and S . Pettersson, function: Role of the aryl-hydrocarbon-receptor Singapore 15.05 Effect of eradication therapy of H . pylori on gut K . Sugano, microbiota Tochigi 15.25 Pre-, pro- and synbiotics for chronic kidney disease K . Campbell, Brisbane 15.45 The microbiome and obesity: Cause, consequence A . Holmes, or both? Sydney 16.05 Oral poster presentation: Reducing the maternal dietary intake of indigestible M . Iacovou, and slowly absorbed short-chain carbohydrates Melbourne is associated with improved infantile colic: A proof-of-concept study 16.15 Oral poster presentation: The prebiotic impact of dietary FODMAPs on E .P . Halmos, intestinal microbiota Melbourne 16.25 Coffee break with poster session 7 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 7 30.03.17 10:49 Friday, May 19, 2017 Session IV Intended and unintended alterations of the human microbiome Chair: J . Gapasin-Tongo, Quezon City; M . Grimm, Sydney 16.45 State-of-the-Art Lecture: P . Moayyedi, Comparative efficacy of traditional treatments and Hamilton treatments targeting the microbiome in IBD and IBS 17.15 The FODMAP diet - A microbiome targeted intervention M . Chen, and what could be the consequences? Guangzhou 17.35 Debate: Faecal microbiota transplantation: Are we ready for prime–time? Chair: W .D . Chey, Ann Arbor PRO: Faecal microbiota transplantation (FMT) – M .A . Kamm, Ready for prime time Melbourne CONTRA J . Andrews, Adelaide 17.55 Summary of the day E .M . El-Omar, Sydney 18.05 Scientific discussion with snacks 8 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 8 30.03.17 10:49 Saturday, May 20, 2017 Session V The gastrointestinal microbiome and extraintestinal diseases Chair: G . Hebbard, Melbourne; B . Kendall, Brisbane 8.30 State-of-the-Art Lecture: E .A . Mayer, Microbiome and brain function in health and disease Los Angeles 9.00 Anxiety and depressive disorders, the inflammasome, M . Gray, and the gut microbiome Brisbane 9.20 Distinct oral and fecal community profiles enriched in R . Thomas, opportunistic pathogens in rheumatoid arthritis patients Brisbane 9.40 Friend or foe: The microbiome in liver disease L . Adams, Perth 10.00 Oral poster presentation: Gut microbiota composition and behaviour problems A . Loughman, in early childhood Melbourne 10.10 Oral poster presentation: Distinct gut microbiota profiles in patients with L . Bajer, primary sclerosing cholangitis and ulcerative colitis Prague 10.20 Coffee break with poster session Session VI Targeting the mucosal microbiome and mucosal immune responses Chair: T . Florin, Brisbane; R W. .L . Leong, Sydney 10.50 State-of-the-Art Lecture: H . Ohno, The function of M cells in host-microbe interactions Yokohama 11.20 The mucosal microbiome of the upper GI tract and E .R . Shanahan, its role in FGIDs Brisbane 11.40 The gut-lung axes and IBD K .M . Fock, Singapore 12.00 The microbiome, autophagy and IBD J . Begun, Brisbane 9 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 9 30.03.17 10:49 Saturday, May 20, 2017 12.20 Characterising local and systemic immune response in A . Do, functional dyspepsia Brisbane 12.40 Oral poster presentation: Esophageal dysbiosis in Barrett‘s esophagus and T -M. -T. Nguyen, esophageal adenocarcinoma Brisbane 12.50 Oral poster presentation: Reduced abundance of Faecalibacterium prausnitzii A S. Raj, in the terminal ileum mucosa-associated microbiome Brisbane correlates with increased small intestinal permeability in chronic liver disease 13.00 Presentation of poster awards P .R . Gibson, Melbourne 13.15 Lunch break with poster session Session VII What are the challenges and opportunities of future approaches to maintain or improve health and wellbeing by targeting the microbiome? Chair: K .M . Fock, Singapore; R . Ward, Brisbane 14.10 State-of-the-Art Lecture: E .M .M . Quigley, The current and future assessment and targeted Houston modulation of the gastrointestinal microbiome in the clinical setting 14.40 The host genes and associations with the microbiome: S C. Ng, Implications for targeted interventions Hong Kong 15.00 Diets, functional foods, such as EEN or PEN and P . Lewindon, inflammatory bowel disease Brisbane 15.20 Coffee break with poster session 15.50 Next generation microbiology: Monitoring the resistome I . Autenrieth, by shot gun metagenomics to fight the spread of Tübingen antimicrobial resistance 16.10 The clinician’s perspective of needs and opportunities U C. Ghoshal, in developing countries Lucknow 10 13635_Falk_Brisbane_Symp_207_Prog_Inhalt.indd 10 30.03.17 10:49 Saturday, May 20, 2017 16.30 Oral poster presentation: A type 1 diabetes associated core microbiome driven by J .A . Mullaney, interleukin 2 pathway and